Aspen Neuroscience’s Personalized Parkinson’s Therapy Shows Promise in Clinical Trial
For the millions of people living with Parkinson’s disease, the search for effective treatments is a constant source of hope and concern. Current therapies manage symptoms but do not stop the progression of the disease. However, recent advancements in cell therapy are offering a new frontier in the fight against Parkinson’s. A New Era for […]
Kenai Therapeutics Gets $8M Boost for Parkinson’s Treatment
A New Hope for Parkinson’s Patients Kenai Therapeutics, a San Diego-based biotechnology company, has received an $8 million grant from the California Institute for Regenerative Medicine (CIRM). This funding will help advance their lead program, RNDP-001, a promising new treatment for idiopathic Parkinson’s disease. The grant was awarded to Dr. Howard J. Federoff, the company’s […]
Parkinson’s Symptoms Reversed: A Stem Cell Breakthrough?
For the 10 million people worldwide living with Parkinson’s disease, the daily battle with tremors, stiffness, and loss of motor control is a constant reality. But a groundbreaking clinical trial in China has delivered a powerful new sense of hope, as a 37-year-old woman has achieved a “functional cure” just three months after receiving a […]
Aspen Neuroscience Advances Parkinson’s Treatment with New Trial Phase
More than one million people in the U.S. live with Parkinson’s disease, a condition with no available disease-modifying therapies. A new development from Aspen Neuroscience offers a potential new direction, as the company initiates a new phase in its clinical trial for a personalized cell therapy. ASPIRO Trial Enters Third Cohort Aspen Neuroscience has announced […]
BlueRock Therapeutics Announces First Patient Treated in Pivotal Phase III Parkinson’s Trial
BlueRock Therapeutics, a subsidiary of Bayer, has announced a significant milestone in the development of a new treatment for Parkinson’s disease. The first patient has been treated in their pivotal Phase III clinical trial, known as exPDite-2. This trial will evaluate the safety and effectiveness of bemdaneprocel, an investigational cell therapy. The trial is the first […]
Stem Cell Research for Parkinson’s: What Patients Need to Know
Is stem cell therapy a viable treatment for Parkinson’s disease? What are the real risks and benefits? In a recent webinar from The Michael J. Fox Foundation for Parkinson’s Research, leading experts shared the latest advances in stem cell science and what they mean for patients. This article summarizes the key takeaways from the webinar, […]
How Exercise Supercharges Stem Cell Therapy for Parkinson’s Disease
In the latest episode of The Stem Cell Report podcast, host Janet Rossant delves into groundbreaking research that explores the synergistic effects of exercise and stem cell therapy in treating Parkinson’s disease. Joined by Dr. Clare Parish and Dr. Niamh Moriarty from The Florey Institute of Neuroscience and Mental Health, the discussion centers on their […]
Stem Cells, Exosomes, and Parkinson’s Disease: A New Hope
Infinite Health Integrative Medicine Center in Louisiana announced progress in Parkinson’s disease treatment through stem cell and exosome innovations. A Phase 1 clinical trial is reprogramming stem cells to replace damaged neurons, showing potential in early results. Dr. Trip Goolsby’s center is using a less invasive exosome therapy to repair brain damage and improve dopamine production. […]
AskBio Receives FDA Regenerative Medicine Advanced Therapy Designation for Parkinson’s
AskBio, a Bayer AG subsidiary, announced that its investigational gene therapy AB-1005 for Parkinson’s disease received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA.? This designation was based on promising Phase Ib trial data, showing a favorable safety profile and positive trends in clinical outcomes.? The RMAT designation aims to expedite the development of […]
iRegene Receives IND Approval from U.S. FDA to Start Clinical Trial for Parkinson’s Disease
iRegene Therapeutics has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting Investigational New Drug (IND) approval for their innovative cell therapy, NouvNeu001, aimed at treating Parkinson’s disease. This approval marks a pivotal step forward in the fight against this debilitating neurodegenerative disorder. A New Hope for Parkinson’s Patients Parkinson’s disease, characterized by the loss of dopaminergic neurons, […]